Attenuation of β-amyloid-induced tauopathy via activation of CK2α/SIRT1: Targeting for cilostazol

Journal of Neuroscience Research

Volumn 92, Issue 2, 2014, Pages 206-217

  Lee, Hye Rin ^a   Shin, Hwa Kyoung ^a   Park, So Youn ^a   Kim, Hye Young ^a   Lee, Won Suk ^a,b   Rhim, Byung Yong ^b   Hong, Ki Whan ^a   Kim, Chi Dae ^a,b  

^a Pusan National University   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

amyloid; Cilostazol; CK2 ; SIRT1; Tau, GSK 3

Indexed keywords

AMYLOID BETA PROTEIN; CILOSTAZOL; E1A ASSOCIATED P300 PROTEIN; HISTONE ACETYLTRANSFERASE; KT 5720; RESVERATROL; SIRTINOL; SIRTUIN 1; TAU PROTEIN;

ACETYLATION; ANIMAL CELL; ARTICLE; ATTENUATION; CELL ASSAY; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVATION; EXPRESSION VECTOR; GENE SILENCING; GENETIC TRANSFECTION; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TAUOPATHY;

CILOSTAZOL; CK2Α; SIRT1; TAU, GSK-3Β; Β-AMYLOID;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOTTING, WESTERN; CELL LINE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KERATIN-2; MICE; NEURONS; NEUROPROTECTIVE AGENTS; SIRTUIN 1; TAU PROTEINS; TAUOPATHIES; TETRAZOLES; TRANSFECTION;

EID: 84890126689     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23310     Document Type: Article

References (28)

1. Anekonda TS, Reddy PH. 2006. Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem 96:305-313.
2. Araki T, Sasaki Y, Milbrandt J. 2004. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305:1010-1013.
3. Avila J, Lucas JJ, Perez M, Hernandez F. 2004. Role of tau protein in both physiological and pathological conditions. Physiol Rev 84:361-384.
4. Ballatore C, Lee VMY, Trojanowski JQ. 2007. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8:663-672.
5. Bannister AJ, Kouzarides T. 1996. The CBP co-activator is a histone acetyltransferase. Nature 384:641-643.
6. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert, MA, Crump NT, Hazzalin CA, Liszczak G, Yuan H, Larocca C, Saldanha SA, Abagyan R, Sun Y, Meyers DJ, Marmorstein R, Mahadevan LC, Alani RM, Cole PA. 2010. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 17:471-482.
7. Cohen TJ, Guo JL, Hurtado DE, Kwong, LK, Mills IP, Trojanowski JQ, Lee VMY. 2011. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2:252-262.
8. Fusco S, Ripoli C, Podda MV, Ranieri SC, Leone L, Toietta G, McBurney MW, Schütz G, Riccio A, Grassi C, Galeotti T, Pani G. 2012. A role for neuronal cAMP responsive-element binding (CREB)-1 in brain responses to calorie restriction. Proc Natl Acad Sci U S A 109:621-626.
9. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
10. Hiramatsu M, Takiguchi O, Nishiyama A, Mori H. 2010. Cilostazol prevents amyloid β peptide 25-35-induced memory impairment and oxidative stress in mice. Br J Pharmacol 161:1899-1912.
11. Hooper C, Killick R, Lovestone S. 2008. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104:1433-1439.
12. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N, Sato K. 2003. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A 100:6370-6375.
13. Howitz, KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191-196.
14. Jämsä A, Hasslund K, Cowburn RF, Bäckström A, Vasänge M. 2004. The retinoic acid and brain-derived neurotrophic factor-differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation. Biochem Biophys Res Commun 319:993-1000.
15. Julien C, Tremblay C, Emond V, Lebbadi M, Salem N, Bennett DA, Calon F. 2009. SIRT1 decrease parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68:48-74.
16. Kang H, Jung JW, Kim MK, Chung JH. 2009. CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage. PLoS One 14:4:e6611.
17. Kar S, Fan J, Smith MJ, Goedert M, Amos LA. 2003. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J 22:70-77.
18. Klein WL, Stine WB Jr, Teplow DB. 2004. Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25:569-580.
19. Lee HR, Park SY, Kim HY, Shin HK, Lee WS, Rhim BY, Hong KW, Kim CD. 2012. Protection by cilostazol against amyloid-β(1-40)-induced suppression of viability and neurite outgrowth through activation of CK2α in HT22 mouse hippocampal cells. J Neurosci Res 90:1566-1576.
20. Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, Martin V A, Tronche F, Kellendonk C, Gau D, Kapfhammer J, Otto C, Schmid W, Schütz G. 2002. Disruption of CREB function in brain leads to neurodegeneration. Nat Genet 31:47-54.
21. Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ. 2002. First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 45:1292-1299.
22. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah C, Mukherjee C, Cole PA, Ott M, Gan L. 2010. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67:953-966.
23. Noriega LG, Feige JN, Canto C, Yamamoto H, Yu J, Herman MA, Mataki C, Kahn BB, Auwerx J. 2011. CREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability. EMBO Rep 12:1069-1076.
24. Outeiro TF, Marques O, Kazantsev A. 2008. Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta 1782:363-369.
25. Pagano MA, Poletto G, Di Maira G, Cozza G, Ruzzene M, Sarno S, Bain J, Elliott M, Moro S, Zagotto G, Meggio F, Pinna LA. 2007. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochemistry 8:129-139.
26. Park SH, Kim JH, Bae SS, Hong KW, Lee DS, Leem JY, Choi BT, Shin HK. 2011. Protective effect of the phosphodiesterase III inhibitor cilostazol on beta-amyloid-induced cognitive deficits associated with decreased amyloid b accumulation. Biochem Biophys Res Commun 408:602-608.
27. Stambolic V, Woodgett JR. 1994. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 303:701-704.
28. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. 2002. Amyloid b-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A 99:13217-13221.